Psyence Biomedical Ltd. PBM 深 沪
已收盘 02-06 16:00:00 美东时间
3.13
+0.240
+8.30%
华盛通- 最 高3.27
- 今 开2.85
- 成交量 10.44万股
- 最 低 2.7501
- 昨 收 2.89
- 总市值 319.94万
- 52周最高 74.9375
- 市盈率 静 0.28
- 换手率 10.21%
- 52周最低 2.535
- 委 比 82.82%
- 总股本 102.22万
- 历史最高 392.0244
- 量 比 0.08
- 振 幅 17.99%
- 历史最低 2.7501
- 每 手 1
- 风险率 15.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Teradyne Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
Shares of Teradyne Inc (NASDAQ:TER) rose sharply in pre-market trading after th...
02-03 17:42
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
Psyence Biomedical Ltd. has postpone its annual and special shareholder meeting until February 12, 2026, due to insufficient shareholder quorum. The meeting will take place in Cape Town, South Africa. The company is working with proxy agents to ensure quorum for the reconvened meeting. The record date remains December 23, 2025. Psyence BioMed is a biopharmaceutical company developing nature-derived psychedelic medicines for mental health treatmen...
01-22 18:42
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers PAVmed (NASDAQ:PAVM) stock increased by 250.7% to $21.71 during Wednes...
01-22 01:05
Psyence Biomedical sets Jan. 20 as effective date for reverse stock split
Psyence Biomedical (PBM) has announced the effective date of its 1-for-6.25 reverse stock split of the company's issued and outstanding common shares. The common shares are expected to begin trading o...
01-15 14:46
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Psyence Biomedical Ltd. (Nasdaq: PBM) announced the effective date of its 1-for-6.25 share consolidation, which will begin trading on January 20, 2026. The consolidation will reduce the number of issued shares from 6,388,604 to 1,022,177, with no fractional shares issued. Shareholders will not see a change in their percentage ownership, except for minor adjustments due to fractional share rounding. The new CUSIP number is 74449F407. The company f...
01-15 00:00
Psyence Biomedical Announces Production Of GMP-Compliant, High-Purity Ibogaine Hydrochloride Derives From Naturally Extracted Source In Africa
Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a
01-05 22:17
Market-Moving News for December 19th
NKE: -10% | Nike shares are trading lower. The company reported a 17% decline in Greater China sales in Q2. KBH: -7% | KB Home shares are trading lower. The company reported Q4 financial results. PBM:
2025-12-19 20:21
Psyence BioMed shares are trading higher after the CEO's year-end letter highlighted progress on its Phase IIb psilocybin trial, ethical ibogaine sourcing in Africa, and its cash position.
Psyence BioMed shares are trading higher after the CEO's year-end letter highli...
2025-12-09 20:58
Psyence Secures Long-Term Supply Of Plant-Based Drug Ingredient For Addiction Treatment Research, Moves Closer To Clinical Trials With New Source Of Ibogaine For Substance Use Therapies
Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today
2025-11-20 20:10
Psyence BioMed Expands Through PsyLabs, Establishing Exclusive Public Market Presence In Africa For Ibogaine & Psilocybin Development
Psyence BioMed (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that, through its
2025-11-12 20:12
